Association of Weight Change, Inflammation Markers and Disease Staging with Survival of Patients Undergoing Chemotherapy for Pancreatic Adenocarcinoma

Matos, Leonor Vasconcelos de; Coelho, Ana Rita; Cunha, R.; Fernandes, Leonor; Sousa, Marta; Neves, Maria Teresa; Cardoso, Débora; Malheiro, Mariana; Graça, Joana; Silva, Eugénia Santos; Plácido, Ana; Martins, Ana

doi:10.1080/01635581.2021.1903049

Cited by 4 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Weight loss during treatment of pancreatic cancer is a prognostic though this may be modified based on the degree of weight loss, the starting BMI, the timeframe of weight loss, the precision of measuring weight, and the type of weight loss whether arising from skeletal muscle, visceral and/or subcutaneous fat and/or whether inflammatory markers or tumor markers such as the CA19.9 are present. 8-12…”

Section: Introductionmentioning

confidence: 99%

“…4,7 Weight loss during treatment of pancreatic cancer is a prognostic though this may be modified based on the degree of weight loss, the starting BMI, the timeframe of weight loss, the precision of measuring weight, and the type of weight loss whether arising from skeletal muscle, visceral and/or subcutaneous fat and/or whether inflammatory markers or tumor markers such as the CA19.9 are present. [8][9][10][11][12] The ability to predict potentially short survival early in palliative treatment or during neoadjuvant chemotherapy may be helpful in the timing of palliative care in this group of patients. Though, some would suggest that palliative care should be started in all patients with incurable pancreatic cancer at diagnosis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Is Weight Loss During Chemotherapy for Pancreatic Cancer Prognostic?

Davis

Vanenkevort

Varun

et al. 2022

Am J Hosp Palliat Care

View full text Add to dashboard Cite

Background Predicting poor survival outcomes early in palliative chemotherapy is important to the timing of palliative care. Weight loss during chemotherapy if prognostic would lead to early palliative care. Method We collected demographics, stage, chemotherapy, chemotherapy cycles, weight, healthcare utilization, comorbidities (Charleson Comorbid Index), tumor markers, and weight changes over 60 days. We defined 3 groups of patients: 1. Weight gain to <.5% weight loss, 2. Weight loss< 2% and 3. Weight loss of >2%. A Chi-square test assessed differences in weight during treatment. Time-to-event analysis was expressed in a Kaplan Meier curve. Results 93 individuals died of pancreatic cancer in 2018 and 2019. The median age was 71.2 years. Forty-three had stage I and II, 40 stages III and IV cancers, and 10 had unknown stages. Most received FOLFIRINOX and gemcitabine/nab-paclitaxel chemotherapy. Thirty-six gained to lost < .5% during chemotherapy,8 lost < 2% and 49 patients lost > 2% of their weight. Mortality was available in 55 of 93 patients. Median survival was 16.6 months in those with weight gain to < .5% weight loss, 17.28 months for those with < 2% weight loss, and 20.5 months for those with > 2% weight loss ( P = .42). Discussion Weight loss over 60 days did not predict a poor prognosis in this small retrospective study; larger prospective studies may clarify the prognostic importance of weight loss during chemotherapy. Conclusion In this small retrospective study, weight loss over 60 days did not predict poor survival.

show abstract

Section: Introductionmentioning

confidence: 99%